← Leaderboards
Avelina Espinosa
University Of Rhode Island
$619,157
Attributed
$619,157
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $103.4K · FY2005–11$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$619,157 · 7
By mechanism
P20$619,157 · 7
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Fermentation”
- Eric S Lander · Whitehead Institute For Biomedical Res$245,709,979
- David Heimbrook · Leidos Biomedical Research, Inc.$66,520,987
- Stephen Kevin Burley · Sgx Pharmaceuticals, Inc.$46,173,838
- Sean F Brady · Rockefeller University$18,458,623
- Dallas Hughes · Novobiotic Pharmaceuticals, Llc$16,618,718
- Larry Arthur$16,266,310
Research focus
FermentationDrug ToxicitySourcePharmaceutical PreparationsAmebiasisEnzymesGrantEntamoeba HistolyticaResourcesFundingToxic EffectEhadh2 EnzymeGrowthUnited States National Institutes Of HealthInstitutionAntimicrobialStagingComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelLife Cycle StagesCystInhibitor/AntagonistDesignComputer Simulation
Grant awards (7)
IDENTIFICATION OF NEW DRUGS AGAINST AMEBIASIS$69,696
P20 · FY2011 · RR · contact PI
IDENTIFICATION OF NEW DRUGS AGAINST AMEBIASIS$68,432
P20 · FY2010 · RR · contact PI
SEARCH FOR ANTI-AMOEBIC DRUGS W/ LESS TOXICITY IN HUMANS: ENTAMOEBA HISTOLYTICA$80,199
P20 · FY2009 · RR · contact PI
SEARCH FOR ANTI-AMOEBIC DRUGS WITH LESS TOXICITY IN HUMANS: ENTAMOEBA HISTOLYTI$93,321
P20 · FY2008 · RR · contact PI
SEARCH FOR ANTI-AMOEBIC DRUGS WITH LESS TOXICITY IN HUMANS: ENTAMOEBA HISTOLYTI$102,684
P20 · FY2007 · RR · contact PI
SEARCH FOR ANTI-AMOEBIC DRUGS WITH LESS TOXICITY IN HUMANS: ENTAMOEBA HISTOLYTI$101,393
P20 · FY2006 · RR · contact PI
SEARCH FOR ANTI-AMOEBIC DRUGS WITH LESS TOXICITY IN HUMANS: ENTAMOEBA HISTOLYTIC$103,432
P20 · FY2005 · RR